PANZYGA: payments to doctors
Payments that named PANZYGA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.2M
- Providers
- 9,413
- Transactions
- 40,526
- Average per transaction
- $30
The per-transaction average — $30 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 9,413 providers the average total is $127, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Pfizer | $688,238 | 57.5% |
| Octapharma USA, Inc. | $458,485 | 38.3% |
| Hospira, Inc. | $49,535 | 4.1% |
| PBG Puerto RICO LLC | $1,192 | 0.1% |